Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by immune dysregulation that results in the production of autoantibodies, generation of circulating immune complexes, and activation of the complement system. The origin of autoantibody production is an area of intense research interest; the contributions of an antigen-driven process (1,2), primary B cell hyperresponsiveness (3,4), or impaired tolerance (5-7) have been debated. A role in SLE for impaired processing of immune complexes due to decreased CR1 expression (8), impaired Fc receptor function (9, lo), and inherited deficiencies of early complement components (1 1) has also been indicated by experimental data.A pathologic hallmark of SLE is the recurrence of widespread and diverse vascular lesions. Although the etiology of the processes which initiate SLE remains uncertain, there is a growing understanding of the cellular and molecular events that are responsible for vascular injury. In this review, we present the pathologic spectrum of vascular lesions that can be observed in SLE and discuss immunopathogenic mechanisms that best explain their development (Table 1). Evidence is presented which suggests that the presence of endothelial cell activation may be a key determinant in the localization of vascular pathology.